- Home
- AKA vs CNTB Comparison
AKA vs CNTB Comparison
Compare AKA & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKA | CNTB |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.7M | 128.6M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AKA | CNTB |
|---|---|---|
| Price | $9.82 | $2.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $24.33 | $8.50 |
| AVG Volume (30 Days) | 1.4K | ★ 103.7K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.22 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $600,208,000.00 | $26,033,000.00 |
| Revenue This Year | $5.83 | N/A |
| Revenue Next Year | N/A | $24,617.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 4.44 | N/A |
| 52 Week Low | $7.00 | $0.51 |
| 52 Week High | $16.90 | $3.28 |
Technical Indicators
Market Signals| Indicator | AKA | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 38.64 | 53.95 |
| Support Level | $9.31 | $2.09 |
| Resistance Level | $12.08 | $2.86 |
| Average True Range (ATR) | 0.27 | 0.21 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 17.30 | 36.25 |
Price Performance
Historical ComparisonAbout AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.